Key Points
- Insider Eric So bought 100,000 Cybin shares at an average price of $12.39, investing approximately $1.24 million and increasing his ownership by 2.29% to 4.47 million shares.
- Cybin reported a quarterly loss of $0.91 per share, missing the $0.80 consensus estimate; analysts expect a full-year loss of about $2.95 per share.
- Institutional ownership stands at 17.94%, while analysts maintain a consensus “Buy” rating with an average price target of $48.60, substantially above the stock’s reported $12.97 price.
Cybin Inc. (NASDAQ:HELP - Get Free Report) insider Eric So acquired 100,000 shares of Cybin stock in a transaction dated Tuesday, September 8th. The stock was purchased at an average cost of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the purchase, the insider owned 4,465,014 shares of the company's stock, valued at approximately $55,321,523.46. This represents a 2.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Cybin Price Performance
Shares of HELP stock opened at $12.97 on Friday. Cybin Inc. has a one year low of $3.76 and a one year high of $14.35. The company's fifty day moving average price is $9.97 and its 200-day moving average price is $6.89. The company has a market capitalization of $980.66 million, a price-to-earnings ratio of -4.29 and a beta of 0.63.
Cybin (NASDAQ:HELP - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities research analysts expect that Cybin Inc. will post -2.95 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Pale Fire Capital SE purchased a new position in shares of Cybin in the second quarter valued at $1,015,000. Millennium Management LLC raised its stake in Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock valued at $8,414,000 after purchasing an additional 959,448 shares in the last quarter. Bank of America Corp DE raised its stake in Cybin by 66.8% during the second quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock valued at $247,000 after purchasing an additional 11,790 shares in the last quarter. Osaic Holdings Inc. lifted its position in Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock valued at $63,000 after purchasing an additional 2,400 shares during the last quarter. Finally, AXQ Capital LP bought a new position in Cybin during the second quarter valued at $75,000. 17.94% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on HELP shares. Wall Street Zen raised Cybin from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. TD Cowen boosted their price target on Cybin from $8.00 to $62.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Finally, Wells Fargo & Company started coverage on Cybin in a report on Monday, July 27th. They issued an "overweight" rating and a $16.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cybin presently has a consensus rating of "Buy" and an average price target of $48.60.
Get Our Latest Research Report on HELP
Key Headlines Impacting Cybin
Here are the key news stories impacting Cybin this week:
- Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
- Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
- Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
- Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.
About Cybin
(
Get Free Report)
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
